ACMG 2019: Welcoming Dr. Robert Steiner to Genetics in Medicine
"I am delighted to be appointed Editor-in-Chief (EIC) of Genetics in Medicine as the journal completes its 20th year.
Genetics in Medicine will have a new emphasis on therapeutics; we are after all Genetics in Medicine. Recent and upcoming advances in therapeutics for genetic conditions are absolutely astounding. My hope is that investigators directing clinical trials in genetic conditions will look to Genetics in Medicine to publish their results. Likewise, researchers who develop novel therapeutic approaches will want to publish early phase trials in the journal. Although we are not a basic science journal, authors should be encouraged to submit ground-breaking basic science or animal model manuscripts with direct links to new therapeutic approaches. Even though there are journals devoted to gene therapy/gene editing, Genetics in Medicine encourages submissions of clinically relevant therapeutic reports utilizing those approaches for rare genetic conditions. Cancer genetics will also be emphasized as an area of interest going forward.
I look forward to hearing your ideas for where you think the journal should go, and for reading your submissions to the journal."
Robert D. Steiner, MD
Editor-in-Chief, Genetics in Medicine
University of Wisconsin School of Medicine and Public Health
Introducing Genetics in Medicine’s New Category – Therapeutics
Therapeutics Section Editor, Dwight D. Koeberl, MD, PhD of Duke University School of Medicine. Dr. Koeberl has a long-term research interest in the development of new therapies for rare disorders. He has initiated several clinical trials of new therapies for Pompe disease, including a Phase I clinical trial of liver depot gene therapy.
Call for Submissions
Submissions are now open for a new category of Therapeutics in Genetics in Medicine, the peer-reviewed journal of the American College of Medical Genetics and Genomics (ACMG)!
GIM is interested in Therapeutics submissions including, for example:
Early and late phase clinical trial results, natural history studies that inform future clinical trials, therapeutic biomarker validation, translational studies of gene therapy/editing, novel clinical study design for rare diseases, orphan drug development, and systematic reviews of genetic disease therapies. Manuscripts reporting only animal experiments typically will not be considered.
For more information on the journal and how to submit a manuscript, please visit Genetics in Medicine
